SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS ARTICLE M impact

Formycon Reports Doubled Nine-Month Revenue and Raises Adjusted EBITDA Outlook

Formycon reported revenue of €40.0 million for the first nine months of 2026, versus €19.5 million a year earlier. It maintained 2026 revenue and EBITDA guidance and set adjusted EBITDA guidance at -€15 million to -€5 million. The FDA accepted the filing for its FYB206 pembrolizumab biosimilar candidate.

FYB

Formycon AG reported a consolidated revenue of €40.0 million for the first nine months of 2026, more than doubling the €19.5 million recorded in the same period of the previous year. The company's EBITDA and adjusted EBITDA also showed significant improvement, reaching -€8.9 million and -€14.9 million, respectively. A major operational milestone was achieved with the FDA's acceptance of the regulatory filing for the Pembrolizumab-biosimilar candidate, FYB206. Additionally, the company introduced a new partner-funded development project, FYB286, which establishes a new strategic production partnership.

While the company maintained its 2026 revenue and EBITDA guidance, it adjusted its outlook for adjusted EBITDA to a range of -€15 million to -€5 million.

Related stories